Other · developed by Latigo Biotherapeutics
LTG-001 is an investigational drug studied in Healthy, Acute Pain, Postoperative, Acute Pain.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07102459 | Phase 2 | Acute Pain | Completed | LTGO |
| NCT06774625 | Phase 2 | Acute Pain, Postoperative | Completed | LTGO |
| NCT07341152 | Phase 1 | Pain Management | Completed | LTGO |
| NCT06049095 | Phase 1 | Healthy | Active not recruiting | LTGO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
HealthyAcute PainAcute Pain, PostoperativePain ManagementPostoperative Pain Control
See LTGO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LTGO catalysts and pipeline →